PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOKYO.L Share News (OKYO)

  • There is currently no data for OKYO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Eckoh expects profit up; LXi REIT refinances facility

Tue, 25th Apr 2023 16:19

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Okyo Pharma Ltd - UK-based preclinical biopharmaceutical company - Activates the first clinical trial site in the US for its phase 2, multi-centre, randomised, double-blinded, placebo-controlled trial evaluating the efficacy and safety of the OK-101 ophthalmic solution in subjects with dry eye disease. First patient is expected to make their first visit within the next two weeks. Chief Executive Officer Gary Jacob says: "Our primary focus continues to be on advancing the clinical development of OK-101 as a potential treatment option for dry eye disease, a chronic ocular condition that affects roughly 700 million people worldwide. With the activation of our first clinical site we are now very close to the opening of the OK-101 phase 2 trial and are looking forward to initiating enrolment and completing the trial before the end of the year."

----------

Eckoh PLC - London-based secure payment and customer contact products - Expects revenue for the year that ended March 31 to be GBP39 million, up from GBP31.8 million a year earlier. Expects adjusted operating profit of at least GBP7.6 million from GBP5.2 million, slightly ahead of market expectations. Net cash at March 31 up to GBP5.7 million from GBP2.8 million, also ahead of market expectations. Notes "excellent progress was made in the key North American region" with Security Solutions exit annual recurring revenue up organically 34% to USD15.9 million from USD11.9 million, due to "increasing focus on on its largest growth market, which resulted in further large contract wins, increased cross-selling and strong renewals in the region". Expects to announce its annual results on June 14.

----------

N4 Pharma PLC - Derby, England-based pharmaceutical company focused on developing Nuvec, a delivery system for vaccines and cancer treatments - Says it has now completed work on establishing assays to measure how Nuvec loaded with BCL-2 siRNA can silence expression of the BCL-2 protein. BCL-2 is a form of protein that regulates cell death in healthy cells however aberrant expression can facilitate tumour development and resistance to cancer therapy. Says this means it can now proceed to generate a dose response curve for knockdown of BCL-2 expression to compliment the one already generated for epidermal growth factor receptor. EGFR is found on the surface of some normal cells and is involved in cell growth. It may also be found at high levels on some types of cancer cells, which causes these cells to grow and divide. Says it has planned further work to assess the minimal loading of siRNA on Nuvec to achieve comparable inhibition to the two commercially available drugs. Says next step is to undertake a full dose response curve study for siRNA loaded Nuvec and compare to the dose response for Gefitinib and Venetoclax.

----------

Loungers PLC - Bristol, England-based operator of restaurants including Lounge and Cosy Club - Revenue in the year that ended April 16 is up 20% to GBP283.5 million from a year earlier. Expects earnings before interest, tax, depreciation and amortisation to be broadly in line with market expectations. Like-for-like sales growth up 7.4% from a year earlier and up 18% from pre-pandemic levels three years ago. Opens 29 new sites during the financial year. Chief Executive Officer Nick Collins says: "For almost a decade now we have consistently out-performed the market as we strive to deliver better for our customers and our teams. The inflationary pressure across our supply chain looks to be easing, and our scale and continued growth have allowed us to mitigate much of the impact. We look forward to continued strong performance as we enter [financial 2024]."

----------

PPHE Hotel Group Ltd - Amsterdam, Netherlands-based real estate firm, which operates hotels and resorts - Secures required regulatory approvals for its recently launched European Hospitality Real Estate Fund. Says this enables it to further accelerate its strategy of identifying, acquiring and developing attractive hotel assets across a range of key European markets. Hotels acquired by the fund will be operated by PPHE's hospitality operating platform. It intends to participate in fund for up to EUR50 million. Also extends partnership with Radisson Hotel Group, noting first Radisson RED hotel located in Belgrade, Serbia. Says the Radisson RED Belgrade will be the second hotel to be operated and marketed by PPHE, following the launch of Grand Hotel Brioni in Pula, Croatia, which opened as a Radisson Collection Hotel in May 2022 following an extensive repositioning project. PPHE Chief Executive Officer Boris Ivesha says: "This builds further on our successful 20-year partnership with Radisson Hotel Group, which is founded on trust, collaboration and joint value creation. We are excited about the future of our property portfolio through this enhanced partnership and our entrepreneurial approach to value creation that is possible through our unique business model. We look forward to continuing to unlock a range of exciting opportunities for long-term growth while exciting an ever-growing number of guests around the world."

----------

LXi REIT PLC - London-based commercial real estate-focused investment trust - Completes refinancing with six-year term facility for total GBP1.30 billion and a weighted average capped all-in cost of debt of 4.7%. Chief Executive Officer Freddie Brooks says: "We are pleased to have completed the company's comprehensive refinancing programme, delivering operational flexibility, further diversifying our sources of capital and underpinning our long-term progressive dividend policy. The new facilities represent a positive outcome for the company, despite the challenging economic backdrop, that is testament to the quality of our long-income portfolio."

----------

Guild Esports PLC - London-based e-sports company - Signs sponsorship deal with sports and fashion brand Hummel International Sport & Leisure AS. Says deal is worth up to GBP700,000 in revenue over the duration of the contract, appointing Hummel as Guild's official technical kit partner, receiving exposure on the front of Guild's team jerseys. Hummel will gain exclusive rights to the production and sale of Guild-branded apparel, which will be sold online including Hummel's website and potentially at the high street outlets of major retailers in the UK and Ireland, subject to confirmation in due course. Guild will receive a double-digit share of the merchandising revenues sold through hummel, including performance-linked payments based on certain sales targets being achieved. Based on Guild's sales projections, the combined value of the sponsorship and merchandising deal is estimated at around GBP1 million over the three-year contract term. Says the products are scheduled to go on sale on October 1. Also terminates contract with cryptocurrency exchange Bitstamp from January 2024 to pursue new contracts with other sponsors. Last year, it agreed a three-year GBP4.5 million sponsorship deal with Bitstamp.

----------

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 May 2023 11:22

IN BRIEF: Okyo Pharma to move shares to New York with London delisting

Okyo Pharma Ltd - Guernsey-based ophthalmology-focused bio-pharmaceutical company, currently developing OK-101 to treat dry eye disease - New shares will be listed on Nasdaq in New York from Monday, following a share consolidation and the termination of its American depository share programme. Okyo has been listed on Nasdaq via the ADS programme since May last year. Okyo shares will be de-listed from the London Stock Exchange on Monday. De-listing had been planned for a week ago but was postponed. Each new Okyo share will represent 65 old shares and be equal to one old ADS.

Read more
11 May 2023 14:27

IN BRIEF: Okyo Pharma delays delisting from London trading to May 22

Okyo Pharma Ltd - UK-based ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease - Delays delisting from London Stock Exchange until May 22. Was previously due on Friday. Says this will have no effect on its American depositary shares trading on Nasdaq in New York. In April, it said the decision to cancel its listing was due to the number of shares trading being "negligible and does not justify the associated costs".

Read more
2 May 2023 20:16

TRADING UPDATES: Knights Group buys St James Law and Baines Wilson

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
26 Apr 2023 15:52

UK shareholder meetings calendar - next 7 days

Thursday 27 April 
Admiral Group PLCAGM
AFC Energy PLCAGM
Alliance Trust PLCAGM
AstraZeneca PLCAGM
BP PLCAGM
CLS Holdings PLCAGM
CRH PLCAGM
Dalata Hotel Group PLCAGM
Dial Square Investments PLCAGM
F&C Investment Trust PLCAGM
Flutter Entertainment PLCAGM
Gresham House Renewable Energy VCT 1 PLCAGM
Gresham House Renewable Energy VCT 2 PLCAGM
Helios Towers PLCAGM
Ibstock PLCAGM
International Personal Finance PLCAGM
Kerry Group PLCAGM
London Stock Exchange Group PLCAGM
Pershing Square Holdings LtdAGM
Quixant PLCAGM
Robert Walters PLCAGM
Schroders PLCAGM
Serco Group PLCAGM
STV Group PLCAGM
Synectics PLCAGM
Taylor Wimpey PLCAGM
Tissue Regenix Group PLCAGM
Weir Group PLCAGM
Friday 28 April 
AQRU PLCAGM
Audioboom Group PLCAGM
BBGI Global Infrastructure SAAGM
Everest Global PLCAGM
GetBusy PLCAGM
Greencoat Renewables PLCAGM
Greencoat UK Wind PLCAGM
Hikma Pharmaceuticals PLCAGM
JPMorgan Claverhouse Investment Trust PLCAGM
Kingspan Group PLCAGM
Minoan Group PLCAGM
Pearson PLCAGM
Rotork PLCAGM
Shanta Gold LtdAGM
Smurfit Kappa Group PLCAGM
Symphony International Holdings LtdAGM
Monday 1 May 
no events scheduled 
Tuesday 2 May 
Carr's Group PLCGM re annual report and directors remuneration report
CVC Income & Growth LtdAGM
IOG PLCAGM
Ocado Group PLCAGM
Plus500 LtdAGM
Wednesday 3 May 
Apax Global Alpha LtdAGM
Barclays PLCAGM
GSK PLCAGM
Hyve Group PLCCourt meeting & GM re acquisition by Heron UK Bidco Ltd
Logistics Development Group PLCAGM
Okyo Pharma LtdGM re proposed cancellation of the ordinary shares of no par value
Reach PLCAGM
Reckitt Benckiser Group PLCAGM
Standard Chartered PLCAGM
Tritax Big Box REIT PLCAGM
Unilever PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Apr 2023 10:50

SMALL-CAP WINNERS & LOSERS: African Pioneer secures project clearance

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Tuesday.

Read more
4 Apr 2023 09:08

Okyo Pharma applies to delist from London Stock Exchange due to costs

(Alliance News) - Okyo Pharma Ltd on Tuesday said it has applied to the UK Financial Conduct Authority and the London Stock Exchange PLC to delist its shares from London's Main Market and the standard segments of the FCA's official list.

Read more
4 Apr 2023 08:45

OKYO Pharma to delist from LSE

(Sharecast News) - Ophthalmology-focused bio-pharmaceutical company OKYO Pharma said on Tuesday that it has applied to delist from the London Stock Exchange.

Read more
16 Mar 2023 17:32

TRADING UPDATES: Inspirit Energy reports progress on Inspirit Charger

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
16 Mar 2023 17:31

TRADING UPDATES: Inspirit Energy reports progress on Inspirit Charger

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
28 Feb 2023 16:01

Okyo says OK-101 clears US customs, to be used in phase 2 trial

(Alliance News) - Okyo Pharma Ltd on Tuesday said its good manufacturing practice-packaged OK-101 drug has cleared customs in the US.

Read more
30 Dec 2022 12:28

Okyo Pharma interim loss multiplies, expects to initiate phase 2 trial

(Alliance News) - Okyo Pharma Ltd's half-year loss widened dramatically, while it also said on Friday it expects to initiate phase 2 of a clinical trial of its dry eye disease treatment OK-101 in early 2023.

Read more
22 Dec 2022 21:57

IN BRIEF: Okyo Pharma wins US FDA clearance for dry eye treatment

Okyo Pharma Ltd - London-based ophthalmology-focused bio-pharmaceutical company - Receives clearance of its investigational new drug application from the US Food & Drug Administration to begin a phase two first-in-human clinical study of OK-101 for the treatment dry eye disease.

Read more
6 Dec 2022 21:50

TRADING UPDATES: 7digital loan pact; Okyo Pharma files with SEC

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
21 Nov 2022 21:59

TRADING UPDATES: Okyo Pharma files IND; Reabold Co-CEOs buy shares

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.